Drug
BL B01d1
BL B01d1: highest development phase Phase 2/3, developed by Sichuan Baili Pharmaceutical Co., Ltd.. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Sichuan Baili Pharmaceutical Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| BL-B01D1 NCT07739186 | Phase 2/3 | Non-squamous Non-small Cell Lung Cancer |
| BL-B01D1 NCT07739199 | Phase 2/3 | Squamous Non-small-cell Lung Cancer |
Latest
No recent events.
Follow BL B01d1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.